Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FG001 optical imaging in meningioma and presumed low-grade glioma
2023-000163-31Phase 2Active
- Sponsor
- University of Copenhagen
- Start
- Feb 2023
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FG001 in meningioma and glioma, sponsored by University of Copenhagen. Primary endpoint: Sensitivity of FG001 for detection of tumor tissue in meningioma and presumed low-grade glioma. Started Feb 2023; status: active.
02
Drugs
FG001
03
Conditions
meningiomaglioma
Beyond the preview
Go deeper on 2023-000163-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000163-31.